S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
The single greatest medical breakthrough of all time? (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
WARNING to all American Investors (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
The single greatest medical breakthrough of all time? (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
The single greatest medical breakthrough of all time? (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
WARNING to all American Investors (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
The single greatest medical breakthrough of all time? (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
The single greatest medical breakthrough of all time? (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
WARNING to all American Investors (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
The single greatest medical breakthrough of all time? (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
S&P 500   4,205.52
DOW   33,042.78
QQQ   349.98
The "How" and "Why" of Investing in 5G Stocks
The single greatest medical breakthrough of all time? (Ad)
Did SOFI Technologies Deserve a Price Target Cut to $2.50?
Palantir: The "Sleeper" Play on the AI Revolution
WARNING to all American Investors (Ad)
Keep An Eye On These 5 Small-Cap AI Companies
AI Chip Stock Showdown: The Biggest Winners and Losers
The single greatest medical breakthrough of all time? (Ad)
Workday: Another AI Winner Melting-Up 
Taiwan Semiconductor Well Positioned for the AI Rush
NASDAQ:XBIO

Xenetic Biosciences (XBIO) Stock Forecast, Price & News

$3.19
+0.05 (+1.59%)
(As of 05/30/2023 ET)
Compare
Today's Range
$3.11
$3.24
50-Day Range
$2.66
$5.18
52-Week Range
$2.40
$10.00
Volume
10,280 shs
Average Volume
64,619 shs
Market Capitalization
$4.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00

Xenetic Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,153.9% Upside
$40.00 Price Target
Short Interest
Healthy
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Xenetic Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.61) to ($0.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars


XBIO stock logo

About Xenetic Biosciences (NASDAQ:XBIO) Stock

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

XBIO Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
XBIO Xenetic Biosciences, Inc.
XBIO.PH - | Stock Price & Latest News | Reuters
See More Headlines
Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

XBIO Company Calendar

Last Earnings
3/23/2023
Today
5/30/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XBIO
Fax
N/A
Employees
4
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$40.00
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+1,153.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-6,550,000.00
Net Margins
-302.29%
Pretax Margin
-302.23%

Debt

Sales & Book Value

Annual Sales
$1.71 million
Book Value
$9.00 per share

Miscellaneous

Free Float
1,403,000
Market Cap
$4.85 million
Optionable
Not Optionable
Beta
2.76

Social Links


Key Executives

  • Mr. Jeffrey F. Eisenberg (Age 53)
    CEO & Director
  • Mr. James F. Parslow (Age 54)
    CFO, COO & Corp. Sec.
  • Dr. Curtis A. Lockshin (Age 59)
    Chief Scientific Officer













XBIO Stock - Frequently Asked Questions

Should I buy or sell Xenetic Biosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares.
View XBIO analyst ratings
or view top-rated stocks.

What is Xenetic Biosciences' stock price forecast for 2023?

1 equities research analysts have issued 12 month price targets for Xenetic Biosciences' stock. Their XBIO share price forecasts range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 1,153.9% from the stock's current price.
View analysts price targets for XBIO
or view top-rated stocks among Wall Street analysts.

How have XBIO shares performed in 2023?

Xenetic Biosciences' stock was trading at $2.8510 at the beginning of the year. Since then, XBIO stock has increased by 11.9% and is now trading at $3.19.
View the best growth stocks for 2023 here
.

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 800 shares, a decrease of 77.8% from the April 30th total of 3,600 shares. Based on an average daily trading volume, of 19,900 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the company's shares are sold short.
View Xenetic Biosciences' Short Interest
.

When is Xenetic Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our XBIO earnings forecast
.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) released its earnings results on Thursday, March, 23rd. The company reported ($1.00) earnings per share for the quarter. The business earned $0.49 million during the quarter, compared to the consensus estimate of $0.18 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 41.39% and a negative net margin of 302.29%.

When did Xenetic Biosciences' stock split?

Xenetic Biosciences's stock reverse split before market open on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX).

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

Who are Xenetic Biosciences' major shareholders?

Xenetic Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.66%) and Susquehanna International Group LLP (0.51%).

How do I buy shares of Xenetic Biosciences?

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $3.19.

How much money does Xenetic Biosciences make?

Xenetic Biosciences (NASDAQ:XBIO) has a market capitalization of $4.85 million and generates $1.71 million in revenue each year. The company earns $-6,550,000.00 in net income (profit) each year or ($4.10) on an earnings per share basis.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The official website for the company is www.xeneticbio.com. The company can be reached via phone at 781-778-7720 or via email at xbio@jtcir.com.

This page (NASDAQ:XBIO) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -